These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 29727311)
1. Identifying Clinical Factors Which Predict for Early Failure Patterns Following Resection for Pancreatic Adenocarcinoma in Patients Who Received Adjuvant Chemotherapy Without Chemoradiation. Walston S; Salloum J; Grieco C; Wuthrick E; Diaz DA; Barney C; Manilchuk A; Schmidt C; Dillhoff M; Pawlik TM; Williams TM Am J Clin Oncol; 2018 Dec; 41(12):1185-1192. PubMed ID: 29727311 [TBL] [Abstract][Full Text] [Related]
2. Patterns of Failure for Lymph Node-Positive Resected Pancreatic Adenocarcinoma After Adjuvant Radiotherapy or Gemcitabine-based Chemotherapy Alone. McDonald AM; Dulaney CR; López-Araujo J; Posey JA; Keene KS; Christein JD; Heslin MJ; Wood TE; Jacob R J Gastrointest Cancer; 2015 Jun; 46(2):149-55. PubMed ID: 25782589 [TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and adjuvant chemoradiation therapy after pancreaticoduodenectomy for pancreatic adenocarcinoma. You DD; Lee HG; Heo JS; Choi SH; Choi DW J Gastrointest Surg; 2009 Sep; 13(9):1699-706. PubMed ID: 19582512 [TBL] [Abstract][Full Text] [Related]
4. Adjuvant interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: a single-institution phase II study. Linehan DC; Tan MC; Strasberg SM; Drebin JA; Hawkins WG; Picus J; Myerson RJ; Malyapa RS; Hull M; Trinkaus K; Tan BR Ann Surg; 2008 Aug; 248(2):145-51. PubMed ID: 18650621 [TBL] [Abstract][Full Text] [Related]
5. Survival benefit of adjuvant chemoradiotherapy for positive or close resection margin after curative resection of pancreatic adenocarcinoma. Kim BH; Kim K; Jang JY; Kwon W; Kim H; Lee KH; Oh DY; Kim H; Lee KB; Chie EK Eur J Surg Oncol; 2020 Nov; 46(11):2122-2130. PubMed ID: 32782200 [TBL] [Abstract][Full Text] [Related]
6. Interferon-based chemoradiation followed by gemcitabine for resected pancreatic adenocarcinoma: long-term follow-up. Ohman KA; Liu J; Linehan DC; Tan MC; Tan BR; Fields RC; Strasberg SM; Hawkins WG HPB (Oxford); 2017 May; 19(5):449-457. PubMed ID: 28162923 [TBL] [Abstract][Full Text] [Related]
8. Induction Chemotherapy Followed by Concurrent Full-dose Gemcitabine and Intensity-modulated Radiation Therapy for Borderline Resectable and Locally Advanced Pancreatic Adenocarcinoma. Badiyan SN; Olsen JR; Lee AY; Yano M; Menias CO; Khwaja S; Wang-Gillam A; Strasberg SM; Hawkins WG; Linehan DC; Myerson RJ; Parikh PJ Am J Clin Oncol; 2016 Feb; 39(1):1-7. PubMed ID: 26132367 [TBL] [Abstract][Full Text] [Related]
9. Predictors of Response and Survival in Locally Advanced Adenocarcinoma of the Pancreas Following Neoadjuvant GTX with or Without Radiation Therapy. Sherman WH; Hecht E; Leung D; Chu K Oncologist; 2018 Jan; 23(1):4-e10. PubMed ID: 29212734 [TBL] [Abstract][Full Text] [Related]
10. Phase 2 study of erlotinib combined with adjuvant chemoradiation and chemotherapy in patients with resectable pancreatic cancer. Herman JM; Fan KY; Wild AT; Hacker-Prietz A; Wood LD; Blackford AL; Ellsworth S; Zheng L; Le DT; De Jesus-Acosta A; Hidalgo M; Donehower RC; Schulick RD; Edil BH; Choti MA; Hruban RH; Pawlik TM; Cameron JL; Laheru DA; Wolfgang CL Int J Radiat Oncol Biol Phys; 2013 Jul; 86(4):678-85. PubMed ID: 23773391 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of adjuvant chemoradiation therapy with capecitabine after resection of pancreatic ductal adenocarcinoma: a retrospective review. Kim ST; Lee J; Park SH; Lee JK; Lee KT; Lee KH; Heo JS; Choi SH; Choi DW; Park YS; Lim HY; Kang WK; Jang KT; Park HC; Lim DH; Park JO Am J Clin Oncol; 2012 Oct; 35(5):432-8. PubMed ID: 21606820 [TBL] [Abstract][Full Text] [Related]
12. Adjuvant PEFG (cisplatin, epirubicin, 5-fluorouracil, gemcitabine) or gemcitabine followed by chemoradiation in pancreatic cancer: a randomized phase II trial. Reni M; Balzano G; Aprile G; Cereda S; Passoni P; Zerbi A; Tronconi MC; Milandri C; Saletti P; Rognone A; Fugazza C; Magli A; Di Muzio N; Di Carlo V; Villa E Ann Surg Oncol; 2012 Jul; 19(7):2256-63. PubMed ID: 22237835 [TBL] [Abstract][Full Text] [Related]
13. Downstaging in pancreatic cancer: a matched analysis of patients resected following systemic treatment of initially locally unresectable disease. Bickenbach KA; Gonen M; Tang LH; O'Reilly E; Goodman K; Brennan MF; D'Angelica MI; Dematteo RP; Fong Y; Jarnagin WR; Allen PJ Ann Surg Oncol; 2012 May; 19(5):1663-9. PubMed ID: 22130621 [TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter? Chen KT; Devarajan K; Milestone BN; Cooper HS; Denlinger C; Cohen SJ; Meyer JE; Hoffman JP Ann Surg Oncol; 2014 Feb; 21(2):662-9. PubMed ID: 24276638 [TBL] [Abstract][Full Text] [Related]
15. Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer. Lee KH; Chie EK; Im SA; Kim JH; Kwon J; Han SW; Oh DY; Jang JY; Kim JS; Kim TY; Bang YJ; Kim SW; Ha SW Cancer Res Treat; 2021 Oct; 53(4):1096-1103. PubMed ID: 33421976 [TBL] [Abstract][Full Text] [Related]
16. Results and patterns of failure in patients treated with adjuvant combined chemoradiation therapy for resected pancreatic adenocarcinoma. Hattangadi JA; Hong TS; Yeap BY; Mamon HJ Cancer; 2009 Aug; 115(16):3640-50. PubMed ID: 19514088 [TBL] [Abstract][Full Text] [Related]
17. Prospective phase I study of capecitabine and oxaliplatin concurrent with radiation therapy for the treatment of locally advanced pancreatic adenocarcinoma, and retrospective comparison to concurrent 5-fluorouracil/radiation and gemcitabine/radiation. Hazard L; Jones K; Shaban A; Anker C; Scaife C; Weis J; Mulvihill S J Gastrointest Cancer; 2012 Jun; 43(2):258-66. PubMed ID: 21243531 [TBL] [Abstract][Full Text] [Related]
18. Completion of Adjuvant Chemotherapy After Upfront Surgical Resection for Pancreatic Cancer Is Uncommon Yet Associated With Improved Survival. Altman AM; Wirth K; Marmor S; Lou E; Chang K; Hui JYC; Tuttle TM; Jensen EH; Denbo JW Ann Surg Oncol; 2019 Nov; 26(12):4108-4116. PubMed ID: 31313044 [TBL] [Abstract][Full Text] [Related]
19. Impact of early disease progression and surgical complications on adjuvant chemotherapy completion rates and survival in patients undergoing the surgery first approach for resectable pancreatic ductal adenocarcinoma - A population-based cohort study. Labori KJ; Katz MH; Tzeng CW; Bjørnbeth BA; Cvancarova M; Edwin B; Kure EH; Eide TJ; Dueland S; Buanes T; Gladhaug IP Acta Oncol; 2016; 55(3):265-77. PubMed ID: 26213211 [TBL] [Abstract][Full Text] [Related]
20. Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: treatment variables and survival duration. Breslin TM; Hess KR; Harbison DB; Jean ME; Cleary KR; Dackiw AP; Wolff RA; Abbruzzese JL; Janjan NA; Crane CH; Vauthey JN; Lee JE; Pisters PW; Evans DB Ann Surg Oncol; 2001 Mar; 8(2):123-32. PubMed ID: 11258776 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]